Status:
COMPLETED
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
Eligibility Criteria
Inclusion
- Hospitalized patients with schizophrenia or schizoaffective disorder
- At least a 6th grade reading level
- Males or females, between 18 and 70 years of age at the time of consent
- Subjects must have been hospitalized for no more than 14 consecutive days immediately prior to screening
Exclusion
- Psychiatric disorder other than schizophrenia or schizoaffective disorder
- History of arrhythmia, heart attack, or heart failure
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT00634348
Start Date
April 1 2004
End Date
March 1 2005
Last Update
February 21 2021
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anaheim, California, United States, 92804
2
Pfizer Investigational Site
Cerritos, California, United States, 90703
3
Pfizer Investigational Site
Culver City, California, United States, 90232
4
Pfizer Investigational Site
Garden Grove, California, United States, 92845